PUBLIC COMPANY
save$ATOSATOSSA THERAPEUTICS, INC.
$ATOSSeattle, WA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- phase2Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
- phase2A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
- —The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Mar 27, 26grantQUAY STEVEN C · President & CEO65,000 sh
- Mar 26, 26grantDaniel Mark James · Chief Financial Officer63,000 sh
🐶 Hiring Signal
News
- Atossa Therapeutics founder to be selected as NIAID director — reportSteven Quay, the founder and CEO of clinical-stage biotech Atossa Therapeutics, is likely to be the next director of NIH's National Institute of Allergy and Infectious Diseases, according to a news…endpoints · 15d ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that